Project overview
ON-TRACT focuses on advancing oligonucleotides (ONs) in medicinal chemistry to tackle urgent challenges in treating lung cancer, B-cell malignancies, and chronic inflammation.
天发娱乐棋牌_天发娱乐APP-官网|下载 consortium, consisting of 10 academic research groups, 4 companies, 1 hospital, and 1 non-profit organisation, will address current limitations through an interdisciplinary approach.
The project will deliver:
? highly skilled scientific staff required to fully exploit ON therapeutics for personalised medicine
? top-class training in organic and chemoenzymatic synthesis, ON analysis, and biomedical/medicinal testing
? transferable skills courses, specific industry relevant workshops and public engagement activities
By integrating expertise in chemistry, biology, advanced delivery systems and medicine, the project aims to create a robust framework for oligonucleotide-based therapies. This holistic strategy will not only advance the development of innovative treatments for severe diseases but also set new standards for sustainability and ethical testing in medicinal chemistry.
We will train 14 highly skilled researchers, ready to take on Europe’s challenges in the life sciences sector; our interdisciplinary and intersectoral training programme will give all ON-TRACT researchers the skills needed for a successful career in any sector.
天发娱乐棋牌_天发娱乐APP-官网|下载 consortium, consisting of 10 academic research groups, 4 companies, 1 hospital, and 1 non-profit organisation, will address current limitations through an interdisciplinary approach.
The project will deliver:
? highly skilled scientific staff required to fully exploit ON therapeutics for personalised medicine
? top-class training in organic and chemoenzymatic synthesis, ON analysis, and biomedical/medicinal testing
? transferable skills courses, specific industry relevant workshops and public engagement activities
By integrating expertise in chemistry, biology, advanced delivery systems and medicine, the project aims to create a robust framework for oligonucleotide-based therapies. This holistic strategy will not only advance the development of innovative treatments for severe diseases but also set new standards for sustainability and ethical testing in medicinal chemistry.
We will train 14 highly skilled researchers, ready to take on Europe’s challenges in the life sciences sector; our interdisciplinary and intersectoral training programme will give all ON-TRACT researchers the skills needed for a successful career in any sector.
